SequelSEC

VYCOR MEDICAL INC VYCO

Surgical & Medical Instruments & Apparatus · CIK 0001424768 · Fiscal year ends 1231

Revenue
$1.86M
Fiscal year ended 2025-12-31
Operating income
$33.90K
Fiscal year ended 2025-12-31
Free cash flow
-$18.70K
Fiscal year ended 2025-12-31

VYCOR MEDICAL INC (VYCO) reported revenue of $1.86M and net income of -$72.43K for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from VYCOR MEDICAL INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

VYCOR MEDICAL INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$1.86M$1.59M$1.46M$1.22M$1.39M$1.14M$1.39M$1.51M$1.38M$1.45M
Cost of revenue$302.29K$166.81K$144.95K$140.64K$134.73K$132.46K$134.77K$169.60K$227.13K$184.68K
Gross profit$1.56M$1.42M$1.32M$1.08M$1.26M$1.01M$1.26M$1.34M$1.16M$1.27M
Operating income$33.90K-$9.14K$40.19K-$306.51K-$435.95K-$727.39K-$601.39K-$1.32M-$1.31M-$1.59M
Net income-$72.43K-$107.20K-$69.69K-$404.92K-$435.66K-$822.48K-$796.20K-$1.38M-$1.48M-$1.65M
Research & development$9.96K$15.32K$22.56KUnavailable$15.16K$0$0Unavailable$3.02K$4.74K
Weighted-average diluted sharesshares 33.37Mshares 32.88Mshares 32.60Mshares 31.71MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$70.19K-$106.95K-$63.08K-$399.70K-$408.25K-$800.31K-$670.19K$1.38M$1.48M-$1.65M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.01$-0.01$-0.01$-0.02UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$1.46M$1.36M$1.20M$1.33M$1.61M$1.68M$1.80M$2.18MUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$2.18M$2.19M$2.60M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

VYCOR MEDICAL INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$86.98K$105.65K$57.29K$37.04K$90.94K$46.00K$60.72K$86.48K$206.21K$56.86K
Total assets$830.42K$998.12K$992.30K$860.18K$935.36K$986.52K$1.09M$1.04M$1.45M$1.49M
Current assets$563.42K$619.61K$584.09K$517.76K$487.41K$463.90K$656.43K$629.65K$608.51K$537.09K
Total liabilities$4.92M$4.69M$4.32M$3.80M$3.33M$2.97MUnavailableUnavailableUnavailableUnavailable
Current liabilities$4.78M$4.50M$4.07M$3.65M$3.15M$2.74M$2.45M$1.81M$1.37M$1.51M
Total equity incl. NCI-$4.09M-$3.69M-$3.33M-$2.94M$2.40M-$1.98M-$1.35M-$768.83K$81.44K-$26.44K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$159.20K$146.08K$234.14K$248.87K$207.52K$181.10K$208.35K$203.12K$213.88K$204.07K
Accounts receivable$218.89K$245.26K$215.23K$156.20K$126.10K$159.24K$274.55K$257.47K$110.42K$148.78K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable$150.00K$150.00KUnavailableUnavailableUnavailableUnavailable
Accounts payable$84.76K$147.57K$117.80K$200.04K$227.72K$179.11K$245.41K$92.96K$141.32K$249.95K

Cash flow

VYCOR MEDICAL INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$13.47K$60.11K$29.43K-$217.02K$21.37K-$248.79K-$6.02K-$260.32K-$527.44K-$496.92K
Capital expenditures$5.22K$5.37K$9.39K$2.78K$38.38K$62.05K$52.90K$63.52K$183.26K$57.45K
Investing cash flow-$4.38K-$4.20K-$9.39K-$2.78K-$38.38K-$52.48K-$50.45K-$63.52K-$183.26K-$57.45K
Financing cash flow-$812-$7.55K$211$165.89K$61.94K$286.55K$40.09K$200.42K$863.85K$266.71K
Net change in cash-$18.67K$48.36K$20.26K-$53.91K$44.94K-$14.72K-$17.29K-$119.73K$149.35K-$290.62K
Stock-based compensation$48.84K$26.78K$10.14K$185.61K$341.10K$520.00K$534.94K$625.62K$334.97K$482.11K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$59.52K$59.52K$57.50K$58.23K$66.07K$56.53K$59.88K$166.39K$275.42K$257.58K

Derived

VYCOR MEDICAL INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow-$18.70K$54.74K$20.04K-$219.80K-$17.01K-$310.84K-$58.92K-$323.84K-$710.70K-$554.37K
Gross margin83.8%89.5%90.1%88.5%90.3%88.4%90.3%88.8%83.6%87.3%
Operating margin1.8%-0.6%2.8%-25.1%-31.3%-63.7%-43.2%-87.3%-94.8%-109.5%
FCF margin-1.0%3.4%1.4%-18.0%-1.2%-27.2%-4.2%-21.5%-51.3%-38.2%
SBC / revenue2.6%1.7%0.7%15.2%24.5%45.5%38.4%41.5%24.2%33.2%
Current ratio0.12x0.14x0.14x0.14x0.15x0.17x0.27x0.35x0.44x0.36x
Revenue YoY growth17.2%8.8%19.4%-12.2%22.0%-18.0%-7.7%9.0%-4.7%Unavailable
Net margin-3.9%-6.7%-4.8%-33.1%-31.3%-72.0%-57.2%-91.4%-106.6%-113.7%
R&D / revenue0.5%1.0%1.5%Unavailable1.1%Unavailable0.0%Unavailable0.2%0.3%
CapEx / revenue0.3%0.3%0.6%0.2%2.8%5.4%3.8%4.2%13.2%4.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VYCO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2021-12-31

Difference 4790426 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.